How the National Health Insurance Coverage policy changed the use of lenvatinib for adult patients with advanced hepatocellular carcinoma: a retrospective cohort analysis with real world big data.

Liu, Yanyan; Bao, Yuwen; Huang, Yaxin; Zhang, Mengdie; Li, Xin

Liu, Yanyan; Bao, Yuwen; Huang, Yaxin; Zhang, Mengdie; Li, Xin.

Afiliação

Liu Y; Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, China.
Bao Y; School of Health Policy and Management, Nanjing Medical University, Nanjing, China.
Huang Y; School of Health Policy and Management, Nanjing Medical University, Nanjing, China.
Zhang M; School of Health Policy and Management, Nanjing Medical University, Nanjing, China.
Li X; Department of Regulatory Science and Pharmacoeconomics, School of Pharmacy, Nanjing Medical University, Nanjing, China.

Int J Equity Health ; 22(1): 256, 2023 Dec 11.

Article em En | MEDLINE | ID: mdl-38082426

Assuntos

Carcinoma Hepatocelular; Neoplasias Hepáticas; Adulto; Humanos; Estudos Retrospectivos; Carcinoma Hepatocelular/tratamento farmacológico; Big Data; Neoplasias Hepáticas/tratamento farmacológico; Programas Nacionais de Saúde; Políticas

Palavras-chave

Advanced hepatocellular carcinoma; The national health insurance coverage; The utilization of lenvatinib

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma Hepatocelular / Neoplasias Hepáticas Idioma: En Revista: Int J Equity Health Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google